Literature DB >> 11826418

Adenosine triphosphate infusion increases liver energy status in advanced lung cancer patients: an in vivo 31P magnetic resonance spectroscopy study.

Susanne Leij-Halfwerk1, Hendrik J Agteresch, Paul E Sijens, Pieter C Dagnelie.   

Abstract

We recently observed inhibition of weight loss in patients with advanced nonsmall-cell lung cancer after intravenous infusion of ATP. Because liver ATP levels were found to be decreased in lung cancer patients with weight loss, the present 31P magnetic resonance spectroscopy (MRS) study was aimed at investigating whether ATP infusion restores liver energy status in these patients. Nine patients with advanced nonsmall-cell lung cancer (stage IIIB/IV) were studied 1 week before (baseline) and at 22 to 24 hours of continuous ATP infusion (37-75 microg/kg/min). Localized hepatic 31P MR spectra (repetition time 15 seconds), obtained in the overnight-fasted state, were analyzed for ATP and P(i) content. Ten healthy subjects (without ATP infusion) served as control. Liver ATP levels in lung cancer patients increased from 8.8 +/- 0.7% (relative to total MR-detectable phosphate; mean +/- SE) at baseline to 12.2 +/- 0.9% during ATP infusion (P <.05), i.e., a level similar to that in healthy subjects (11.9 +/- 0.9%). The increase in ATP level during ATP infusion was most prominent in patients with > or = 5% weight loss (baseline: 7.9 +/- 0.7%, during ATP infusion: 12.8 +/- 1.0%, P < 0.01). In conclusion, ATP infusion restores hepatic energy levels in patients with advanced lung cancer, especially in weight-losing patients. These changes may contribute to the previously reported beneficial effects of ATP infusion on the nutritional status of lung cancer patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11826418     DOI: 10.1053/jhep.2002.31318

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

Review 1.  Magnetic resonance spectroscopy to study hepatic metabolism in diffuse liver diseases, diabetes and cancer.

Authors:  Pieter C Dagnelie; Susanne Leij-Halfwerk
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

2.  Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.

Authors:  Iolanda D'Alimonte; Eleonora Nargi; Mariachiara Zuccarini; Paola Lanuti; Patrizia Di Iorio; Patricia Giuliani; Lucia Ricci-Vitiani; Roberto Pallini; Francesco Caciagli; Renata Ciccarelli
Journal:  Purinergic Signal       Date:  2015-05-15       Impact factor: 3.765

Review 3.  Purinergic signalling and cancer.

Authors:  Geoffrey Burnstock; Francesco Di Virgilio
Journal:  Purinergic Signal       Date:  2013-12       Impact factor: 3.765

4.  Physiological levels of ATP negatively regulate proteasome function.

Authors:  Hongbiao Huang; Xiaoyan Zhang; Shujue Li; Ningning Liu; Wen Lian; Emily McDowell; Ping Zhou; Canguo Zhao; Haiping Guo; Change Zhang; Changshan Yang; Guangmei Wen; Xiaoxian Dong; Li Lu; Ningfang Ma; Weihua Dong; Q Ping Dou; Xuejun Wang; Jinbao Liu
Journal:  Cell Res       Date:  2010-08-31       Impact factor: 25.617

Review 5.  Extracellular ATP and cancer: an overview with special reference to P2 purinergic receptors.

Authors:  Tamás Deli; László Csernoch
Journal:  Pathol Oncol Res       Date:  2008-06-25       Impact factor: 3.201

6.  Parametric exploration of the liver by magnetic resonance methods.

Authors:  Paul E Sijens
Journal:  Eur Radiol       Date:  2009-06-06       Impact factor: 5.315

7.  Exogenous adenosine 5'-triphosphate does not improve survival in rats with acute liver failure.

Authors:  Erin P Becker; DongFeng Sun; Gerald Y Minuk
Journal:  Dig Dis Sci       Date:  2007-10-13       Impact factor: 3.199

Review 8.  In-vivo31P-MRS of skeletal muscle and liver: A way for non-invasive assessment of their metabolism.

Authors:  Ladislav Valkovič; Marek Chmelík; Martin Krššák
Journal:  Anal Biochem       Date:  2017-01-21       Impact factor: 3.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.